Journal Homepage: - www.journalijar.com

INTERNATIONAL JOURNAL OF ADVANCED RESEARCH (IJAR)

Article DOI: 10.21474/IJAR01/19434
DOI URL: http://dx.doi.org/10.21474/IJAR01/19434

RESEARCH ARTICLE

CRISPR IN ORAL ONCOLOGY: BRIDGING PRECISION MEDICINE AND ETHICAL CHALLENGES

Dr. Divyabharathi Selvam, Dr. Karthikeyan Vasudevan

Manuscript Info

Manuscript History
Received: 05 July 2024
Final Accepted: 09 August 2024
Published: September 2024

Key words:-
CRISPR, Oral Oncology, Gene Editing, Precision Medicine, Oral Cancer Treatment, Ethical Challenges, Personalized Cancer Therapy, Gene Delivery Systems, Tumor Suppressor Genes, Cancer Diagnostics

Abstract

CRISPR technology has revolutionized gene editing, with implications across various fields, including oncology. In oral cancer research, CRISPR offers unprecedented precision in targeting and modifying cancer-associated genes. However, despite its promise, significant challenges prevent its widespread clinical use. This Perspective article will focus on the critical challenges of CRISPR implementation in oral oncology, such as the technical limitations, ethical concerns, and the need for innovative delivery mechanisms. We propose that addressing these issues could pave the way for more effective and personalized cancer treatments.

Introduction:-

The landscape of cancer treatment has witnessed remarkable advancements in recent years, with gene editing technologies leading the charge toward more precise and targeted therapies. Among these innovations, the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system stands out for its ability to make specific modifications to the genetic code, offering promising applications in oncology. As cancers are largely driven by genetic mutations, the potential to directly edit these mutations provides a powerful approach to both understanding and treating various forms of the disease. Oral cancer, particularly squamous cell carcinoma, represents a significant portion of global cancer cases, and despite advances in treatment, survival rates remain low due to late diagnosis and treatment resistance. This highlights the urgent need for new therapeutic strategies, and CRIPCR technology offers a potential solution by addressing cancer at its genetic roots.[1,2]

The application of CRISPR in oral oncology presents an exciting opportunity to revolutionize how we approach cancer therapy. The technology's precision in targeting cancer-causing genes and restoring the function of tumor suppressors could transform oral cancer treatment, shifting from generalized approaches to highly individualized interventions. However, while the potential is vast, significant challenges stand in the way of its widespread clinical adoption. These challenges include technical limitations, such as ensuring the specificity of gene editing to avoid off-target effects, and practical hurdles, like developing effective delivery systems that can target oral tissues specifically. Furthermore, ethical concerns around gene editing, particularly in humans, continue to provoke debate within the scientific community, raising questions about the responsible use of such powerful technology.

Given the promise of CRISPR technology and the obstacles that still need to be overcome, this Perspective article aims to critically examine the current state of CRISPR's application in oral oncology. The objective is to identify key challenges in its implementation, explore controversial opinions within the field, and propose new directions for research that could help overcome these barriers. By addressing these issues, we can unlock the full potential of

Corresponding Author:- Dr. Divyabharathi Selvam

CRISPR as a transformative tool in the fight against oral cancer, paving the way for more effective and personalized therapies in the near future.[3-5]

Discussion:-

Emerging Science in Oral Oncology

Recent advancements in CRISPRtechnology have marked a transformative period in cancer research, particularly in the field of oral oncology. Oral cancers, especially squamous cell carcinoma, are often driven by genetic mutations that lead to uncontrolled cell growth and tumor formation. Traditional therapies, such as surgery, radiation, and chemotherapy, have seen limited success in advanced stages of oral cancer, leading researchers to explore more innovative approaches. This is where CRISPR technology comes into play, offering a precise method for editing the genome and addressing the underlying genetic causes of cancer.[6]

CRISPRhas enabled scientists to make targeted modifications to cancer-associated genes. One of the most promising applications in oral oncology is the ability to knock out oncogenes, which are genes that, when mutated, drive the progression of cancer. By disrupting these oncogenes, CRISPR can halt or even reverse the growth of cancerous cells. Moreover, CRISPR technology can be used to restore the function of tumor suppressor genes, which normally act as safeguards to prevent uncontrolled cell division. In many oral cancers, these tumor suppressor genes are inactivated by mutations. CRISPR offers the potential to repair these mutations and restore the natural defence mechanisms of the cells.[7,8]

Another breakthrough application of CRISPR in oral oncology is its use in creating genetically modified models of oral cancer. These models are invaluable for studying the biology of the disease and for testing new therapies. CRISPR allows for the development of more accurate and representative cancer models by introducing specific mutations that are observed in human oral cancers. These models can mimic the genetic landscape of tumors, providing insights into how specific mutations contribute to cancer progression and treatment resistance. This, in turn, enables the development of targeted therapies that are tailored to the genetic profile of individual tumors, paving the way for personalized medicine in oral oncology.

CRISPR is also reshaping our understanding of cancer biology by enabling large-scale functional genomics studies. These studies can identify key genetic drivers of oral cancer, revealing new therapeutic targets. For example, by using CRISPR screens, researchers can systematically knock out individual genes across the genome and observe the effects on cancer cell survival and proliferation. This approach can uncover vulnerabilities in cancer cells that were previously unknown, opening up new avenues for drug development. As a result, CRISPR is not only a tool for treating cancer but also a powerful method for advancing our knowledge of the disease at the molecular level.

While these advancements are promising, CRISPR's potential in oral oncology is still in its early stages. The technology's ability to revolutionize cancer treatment hinges on addressing several key challenges that currently limit its clinical application.[9,10]

Challenges and Controversies

Despite its groundbreaking potential, the implementation of CRISPRin oral oncology faces significant challenges that need to be addressed before it can become a routine part of cancer treatment. One of the foremost technical challenges is the issue of off-target effects. CRISPR relies on guide RNA sequences to direct the proteins to specific sites in the genome, where they make precise cuts. However, these guide RNAs are not always perfect in their targeting, and unintended edits can occur at off-target sites. In the context of cancer treatment, off-target effects could potentially disrupt healthy genes, leading to adverse consequences such as secondary cancers or other genetic disorders. Minimizing off-target effects remains a critical area of research to ensure that CRISPR's therapeutic applications are safe and effective.

Another major challenge is the delivery of CRISPR components to the cancerous cells within oral tissues. Efficient delivery systems are essential for ensuring that the CRISPR machinery reaches its intended target without being degraded or triggering an immune response. While several delivery methods, including viral vectors, nanoparticles, and liposomes, have been explored, none have yet proven to be ideal for use in the complex environment of oral tissues. Oral cancers are often located in hard-to-reach areas of the mouth, making localized and controlled delivery

even more challenging. Moreover, the delivery systems must be designed to penetrate the dense extracellular matrix surrounding tumors, which acts as a physical barrier to therapeutic agents.

Ethical considerations also loom large in the discussion of CRISPR's application in cancer treatment. The ability to edit the human genome raises profound ethical questions, particularly when it comes to germline editing, which involves changes that can be passed on to future generations. Although germline editing is not typically considered in cancer therapies, the ethical debate has influenced public perception of CRISPR technology as a whole. Even in the context of somatic cell editing, which does not affect future generations, concerns remain about the long-term consequences of genetic modifications. For example, if CRISPR is used to treat cancer by editing certain genes, what are the potential impacts on other biological processes regulated by those genes? Moreover, there are concerns about equity and access to CRISPR-based treatments. As with many cutting-edge technologies, there is a risk that CRISPR therapies will be expensive and inaccessible to the majority of patients, potentially exacerbating existing health disparities.

The ethical debates surrounding CRISPR have also been fuelled by controversies over its use in clinical trials. In some cases, researchers have moved ahead with CRISPR applications in humans without fully addressing the ethical implications or obtaining adequate informed consent. These controversies highlight the need for a more robust ethical framework that balances the potential benefits of CRISPR technology with the need to protect patient rights and ensure that treatments are administered safely and fairly.

Addressing these challenges will be critical to unlocking the full potential of CRISPRin oral oncology. Future research efforts must focus on overcoming these obstacles while maintaining a commitment to ethical principles.[9-11]

Proposed Directions and Hypotheses

To advance the application of CRISPRin oral oncology, several key research directions must be pursued. One of the most critical areas for future investigation is the development of safer and more efficient delivery systems that can specifically target oral tissues. This will likely involve the design of novel vectors or nanoparticles that can navigate the unique environment of the oral cavity and deliver CRISPR components with high precision. For example, researchers could explore the use of targeted nanoparticles that are engineered to bind selectively to oral cancer cells, thereby enhancing the specificity of the gene-editing process. Additionally, biodegradable delivery systems that release CRISPR components in a controlled manner over time could improve treatment efficacy while minimizing potential side effects.

Another promising research direction is the refinement of CRISPR technology to reduce off-target effects. Advances in bioinformatics and machine learning could be leveraged to design more accurate guide RNAs that minimize unintended edits. Researchers are already working on optimising the proteins themselves to enhance their specificity and reduce the likelihood of off-target activity. By continuing to refine the technology, it may be possible to achieve near-perfect precision in gene editing, making CRISPR a safer option for cancer treatment.

Interdisciplinary collaboration will also be essential to address the ethical and practical challenges associated with CRISPR in oral oncology. Geneticists, oncologists, bioethicists, and policymakers must work together to develop guidelines that ensure the responsible use of CRISPR technology. This includes establishing clear protocols for obtaining informed consent, conducting thorough risk assessments, and ensuring equitable access to CRISPR-based therapies. Collaborative efforts could also focus on creating ethical frameworks that are flexible enough to accommodate the rapidly evolving nature of CRISPR technology while protecting patient rights and public trust.[12,13]

In addition to these practical considerations, future research should explore new hypotheses related to the genetic pathways unique to oral cancer. For example, specific mutations that drive oral cancer may differ from those found in other cancers, presenting unique therapeutic opportunities. Researchers could investigate whether targeting these mutations with CRISPR could yield more effective treatments than current therapies. Similarly, the role of the tumor microenvironment in oral cancer progression could be studied in greater detail, with CRISPR being used to modify the surrounding stromal cells or immune cells to enhance the body’s natural defences against cancer.

Ultimately, the continued evolution of CRISPRtechnology in oral oncology will depend on a combination of technical innovation, ethical considerations, and interdisciplinary collaboration. By pursuing these proposed

research directions, the field can move closer to realising the full potential of CRISPR as a transformative tool for treating oral cancer, improving patient outcomes, and reshaping the future of cancer therapy.

Conclusion:-

CRISPR technology holds transformative potential for oral oncology, particularly in advancing personalized cancer treatment. However, significant challenges remain, including technical, ethical, and practical issues. By addressing these obstacles, we can move closer to realizing the full potential of CRISPR in clinical applications. Future research should focus on refining gene-editing accuracy and developing oral tissue-specific delivery mechanisms. Collaborative efforts across disciplines will be essential to unlock the next phase of innovation in oral cancer therapy.

References:-

1. Redman M, King A, Watson C, King D. What is CRISPR/Cas9, Arch Dis Child Educ Pract Ed. 2016 Aug;101(4):213-5. doi: 10.1136/archdischild-2016-310459. Epub 2016 Apr 8. PMID: 27059283; PMCID: PMC4975809.
2. Hsu PD, Lander ES, Zhang F. Development and Applications of CRISPR-Cas9 for Genome Engineering. Cell 2014;157:1262–78. 10.1016/j.cell.2014.05.010.
3. S V S, Augustine D, Mushtaq S, Baeshen HA, Ashi H, Hassan RN, Alshahrani M, Patil S. Revitalizing oral cancer research: Crispr-Cas9 technology the promise of genetic editing. Front Oncol. 2024 Jun 10;14:1383062. doi: 10.3389/fonc.2024.1383062. PMID: 38915370; PMCID: PMC11194394.
4. Sánchez-Rivera FJ, Jacks T. Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer. (2015) 15:387–95. doi: 10.1038/nrc3950.
5. Zhao Z, Li C, Tong F, Deng J, Huang G, Sang Y. Review of applications of CRISPR-Cas9 gene-editing technology in cancer research. Biol Proced Online. (2021) 23:14. doi: 10.1186/s12575-021-00151-x.
6. Martinez-Lage M, Torres-Ruiz R, Puig-Serra P, Moreno-Gaona P, Martin MC, Moya FJ, et al.. In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells. Nat Commun. (2020) 11:5060.
7. Akram F, Ul Haq I, Ahmed Z, Khan H, Ali MS. CRISPR-Cas9, A promising therapeutic tool for cancer therapy: A review. Protein Pept Lett. (2020) 27:931–44. doi: 10.2174/0929866527666200407112432.
8. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al.. Cancer statistics for the year 2020: An overview. Int J Cancer. (2021) 149(4):778–89. doi: 10.1002/ijc.33588.
9. Chai AWY, Yee PS, Price S, Yee SM, Lee HM, Tiong VK, Gonçalves E, Behan FM, Bateson J, Gilbert J, Tan AC, McDermott U, Garnett MJ, Cheong SC. Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway. Elife. 2020 Sep 29;9:e57761. doi: 10.7554/eLife.57761. PMID: 32990596; PMCID: PMC7591259.
10. S. Vimal, Inamul Hasan Madar, Logalakshmi Thirumani, Lakshmi Thangavelu, Azhagu Madhavan Sivalingam,CRISPR/Cas9: Role of genome editing in cancer immunotherapy,Oral Oncology Reports,Volume 10,2024, 100251,ISSN 2772-9060, https://doi.org/10.1016/j.oor.2024.100251.
11. Patricia Alejandra Chavez-Granados, Ravichandran Manisekaran, Laura Susana Acosta-Torres, Rene Garcia-Contreras, CRISPR/Cas gene-editing technology and its advances in dentistry,Biochimie,Volume 194, 2022,Pages 96-107,ISSN 0300-9084, https://doi.org/10.1016/j.biochi.2021.12.012.
12. Morshedzadeh F, Ghanei M, Lotfi M, Ghasemi M, Ahmadi M, Najari-Hanjani P, Sharif S, Mozaffari-Jovin S, Peymani M, Abbaszadegan MR. An Update on the Application of CRISPR Technology in Clinical Practice. Mol Biotechnol. 2024 Feb;66(2):179-197. doi: 10.1007/s12033-023-00724-z. Epub 2023 Jun 3. PMID: 37269466; PMCID: PMC10239226.
13. Mout R, Ray M, Lee Y-W, Scaletti F, Rotello VM. In vivo delivery of CRISPR/Cas9 for therapeutic gene editing: Progress and challenges. Bioconjugate chemistry. 2017;28(4):880–884. doi: 10.1021/acs.bioconjchem.7b00057.